Spontaneous Remission In Patients With Acute Myeloid Leukemia With T(8;21) Or Cutaneous Myeloid Sarcoma: Two Case Reports And A Review Of The Literature
Zeng, Q., Yuan, Y., Li, P., & Chen, T. (2013). spontaneous remission in patients with acute myeloid leukemia with t(8;21) or cutaneous myeloid sarcoma: two case reports and a review of the literature. Internal medicine (Tokyo, Japan), 52(11), 1227–1233. https://doi.org/10.2169/internalmedicine.52.9505
View Original Source →Abstract
Spontaneous remission (SR) in patients with acute myeloid leukemia (AML) is rare. We herein present two such cases. The first case was of AML-M2 accompanied by a bone marrow cytogenetic analysis revealing 46, XY, t(8;21)(q22,q22). The second case was of isolated cutaneous myeloid sarcoma (MS) that progressed to AML within seven months. Both of the patients had symptoms of infection and anemia and were therefore treated with antibiotics and transfusions. The SR lasted for two months and one month, respectively. Currently, the mechanisms underlying SR remain ambiguous. Possible underlying mechanisms with a review of the related literature are discussed.
Case Details
Disease Location
Bone marrowithlung
Personal Characteristics
31-year-old man, he was a smoker and worked as a painter, none-treated chronic hepatitis b
Clinical Characteristics
History of a one month recurrent fever and a two-week abnormal peripheral hemogram. Laboratory examination showed an increased wbc count of 15.3×10^9/l bm aspiration revealed marked myeloid hyperplasia. A chest x-ray disclosed an infection in the right lower pulmonary field. A sputum culture showed growth of serratia marcescens lung (CT) showed interstitial pneumonia, enlarged lymph nodes in the mediastinum and a pericardial effusion
Remission Characteristics
Bm aspiration was repeated. It showed that the three cellular lineages were within the normal ranges.
Treatment & Mechanisms
Proposed Remission Mechanisms
Immune responses
Clinical Treatment
Levofloxacin, cefepime and tienam rbc transfusion indomethacin and metamizole sodium cefoperazone-sulbactam and meropenem, voriconazole. Chemotherapy with daunorubicin plus cytarabine
Non-Clinical Treatment
None reported